Johnson & Johnson holds the cleaner structural position, with the lead spread across profitability and stability. Bristol-Myers Squibb Company still has the edge on valuation, which keeps the comparison from looking entirely one-sided. The market setup is mixed, without a decisive signal in either direction. The market is not adding a decisive signal either way — the structural read carries the weight.
The comparison is based on similar long-term financial trajectories, not sector labels.
The lead is spread across profitability and stability, rather than sitting in one isolated gap. The overall score gap is 12 points in favour of Johnson & Johnson.
Both operate in: Drug Manufacturers - General
This comparison is based on industry proximity, not on functional trajectory similarity. BMY and JNJ share the same industry classification.
For a similarity-based comparison, see how BMY and Johnson & Johnson each position within their functional peer groups in AssetNext.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
The largest gaps do not all point in the same direction.
Left means cheaper relative valuation. Higher means stronger structure.
The price setup looks more supportive for Johnson & Johnson, but Bristol-Myers Squibb Company still has the stronger structure.
Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.
Capital efficiency adds support, with a 9.5-point ROIC advantage.
Absolute pricing still looks more supportive for Bristol-Myers Squibb Company, with a forward P/E that is 9.8 turns lower there.
The lead is built on both profitability and stability — though valuation still provides a counterweight.
Break down the BMY vs JNJ comparison across all dimensions with the full interactive tool.
Explore how BMY and JNJ each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.